Exelixis beats third-quarter estimates and maintains 2026 revenue guidance

Exelixis reported third-quarter 2026 results on October 29, with revenue of $658.7M and non-GAAP diluted EPS of $0.94, both ahead of estimates. GAAP diluted EPS was $0.85, while U.S. cabozantinib franchise net product revenue reached $605 million, up 11% year over year. The company maintained its full-year 2026 revenue guidance at $2.50B-$2.55B and expects topline results from the phase 3 STELLAR-304 trial in the first quarter of 2027.

The results reinforce cash generation from Exelixis' cabozantinib franchise while the company continues investing in zanzalintinib trials. Exelixis also repurchased approximately $250 million of stock in the quarter, but its maintained revenue outlook was described as slightly below analyst consensus in one report.

  • 1Exelixis reported third-quarter revenue of $658.7M and non-GAAP EPS of $0.94.
  • 2GAAP diluted EPS was $0.85 for the third quarter.
  • 3Full-year 2026 revenue guidance was $2.50B-$2.55B.
  • 4U.S. cabozantinib franchise net product revenue was $605 million, up 11% year over year, while global franchise revenue was $818 million.
  • 5Exelixis repurchased approximately $250 million of common stock during the third quarter.
  • 6The company expects topline results from the phase 3 STELLAR-304 trial in the first quarter of 2027.
  • Material 2 describes $605M as Q3 2026 revenue in its summary, while other materials identify $605M as U.S. cabozantinib franchise revenue and $658.7M as total revenue.

Sources